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Main text 
The CHA2DS2-VASc score has been developed to stratify patients with Atrial 
Fibrillation (AF) with regards to risk of thromboembolism, and is a universally 
accepted guide to antithrombotic therapy in patients with AF.1  
 
However, higher scores have also been recently associated with increased 
mortality in patients with AF2 and recent studies have investigated this 
association further in patients without AF. Such small studies in patients 
without AF determined that an increased CHA2DS2-VASc score was 
associated with increased risk of stroke and thromboembolism3 as well 
increased risk of developing new AF in patients with4 and without prior 
ischaemic stroke.5 
 
In this issue of the Journal Renda et al. present a large study of 22,179 
middle-aged individuals with 18,367 in sinus rhythm.6 The main purpose of 
the study was to assess the prognostic yield of CHA2DS2-VASc score in the 
non-AF population for new onset AF, cardiovascular morbidity and mortality. 
The authors should be congratulated for a well-designed and executed study 
which provides the largest study to date assessing the role of CHA2DS2-VASc 
score as a risk factor for new AF. The participants were stratified according to 
their CHA2DS2-VASc score into 5 different groups (0,1,2,3 and ≥4) and the 
risk of major adverse cardiovascular events was compared between the 
different groups.  
 
Over a 15-year follow up period in the participants with sinus rhythm; they 
identified 5% with an ischaemic stroke, 9% with coronary events, 7% 
cardiovascular mortality and 24% all cause mortality. A CHA2DS2VASc ≥2 
was associated with double the risk of all cause mortality, cardiovascular 
death and ischaemic stroke. Cumulative incidences, absolute and relative 
risks of major adverse events and mortality were greater with increasing 
CHA2DS2VASc score in subjects with and, importantly, without AF. 
 
Moreover, the incidence of AF during the follow up period was 14% and was 
more common with higher CHA2DS2VASc score. More importantly they found 
that CHA2DS2VASc ≥2 was an independent predictor for new onset AF with a 
hazard ratio of 2.2. 
 
Furthermore, a novel and clinically relevant finding was that the incidence of 
ischaemic stroke was similar in patients with a CHA2DS2VASc ≥4 in sinus 
rhythm and patients with a CHA2DS2VASc=2 in AF. This is an important 
finding as it could further help sub-categorise patients with Embolic Stroke of 
Undetermined Source (ESUS) that could potentially benefit from 
anticoagulation.  
 
In conclusion, this large study confirms the predictive role of CHA2DS2VASc 
score for new onset AF in a population based on a large prospective cohort 
over several years of follow up and also identifies that cumulative incidence of 
AF is greater with increasing CHA2DS2VASc strata. Whilst this is not 
surprising as most of the risk factors for AF7 are constituents of the 
CHA2DS2VASc score, it is the first large study to support this.  
 
Finally, although recently published data showed that anticoagulating patients 
with ESUS and sinus rhythm was not superior to antiplatelet therapy in 
preventing stoke recurrence8 the current study by Renda et al,6 would support 
that in future such studies should be directed towards patients at higher risk of 
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